Virpax Pharma leaps nearly fourfold on plan to develop spray against viruses

Virpax Pharmaceuticals

17/08/2021 21:08

(Updates)
    ** Pain drug developer's shares  VRPX.O  surged 265% to a
record high of $15.35 during market hours
    ** Shares slip 5.6% in trading after the bell
    ** Co says the U.S. FDA has indicated that co can pursue
approval of its product MMS019 as a non-prescription drug to be
used an intranasal protective to reduce spread of viruses
 urn:newsml:reuters.com:*:nBw11VJ7Xa
    ** Co says has engaged contract researcher Syneos Health
 SYNH.O  to assist with clinical trials 
    ** The spray is under development for use as an anti-viral
barrier product
    ** Stock was among the most actively traded on U.S.
exchanges with over 149 mln shares changing hands
    ** VRPX halted three times for volatility since the market's
open
    ** Including day's moves, shares have risen ~94% since their
IPO in February

 (Reporting by Manas Mishra and Lisa Mattackal in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))